CYTR - CYTR STOCK NEWS

CytRx Corporation (OTCQB:CYTR) reported its Q1 2021 results, indicating a net loss of $1.3 million, slightly up from $1.2 million in Q1 2020. The company maintains cash reserves of approximately $9.3 million, expected to support operations for the foreseeable future. Strategic collaborations with Orphazyme and ImmunityBio are highlighted, with potential milestone payments from Orphazyme reaching up to $100 million for arimoclomol in Niemann-Pick disease Type C. The ongoing clinical trials of aldoxorubicin for pancreatic cancer by ImmunityBio show promising early survival rates.

CytRx Corporation (OTCQB: CYTR) noted that Orphazyme A/S (NASDAQ: ORPH) reported that its ORARIALS-01 trial for arimoclomol in ALS failed to meet primary and secondary endpoints. However, no significant safety issues were observed during the study. The trial involved 245 patients and aimed to assess the efficacy of arimoclomol compared to placebo. Meanwhile, Orphazyme's applications for arimoclomol for Niemann-Pick disease Type C are under priority review by the FDA, with a PDUFA date set for June 17, 2021. CytRx plans to provide further updates related to its agreement with Orphazyme.

CytRx Corporation (OTCQB: CYTR) reports on Orphazyme A/S (NASDAQ: ORPH) announcing that its phase 2/3 trial of arimoclomol for inclusion body myositis (IBM) failed to meet primary and secondary endpoints. The trial involved 150 patients at 12 North American and European sites. Patients were given either arimoclomol or a placebo over 20 months. No major safety concerns were found, but the results highlight the challenges in developing effective treatments for IBM. CytRx continues to monitor developments with Orphazyme regarding their agreement on arimoclomol.

CytRx Corporation (OTCQB: CYTR) announced its financial results for the fiscal year 2020, reporting a net loss of $6.7 million, an improvement from $7.2 million in 2019. The company ended the year with approximately $10 million in cash, sufficient for ongoing operations. Key highlights include potential milestone payments from Orphazyme of up to $10 million in 2021 and up to $343 million from ImmunityBio. CytRx is also in the LD Micro Index, reflecting its market position. The CEO expressed optimism about upcoming regulatory approvals for arimoclomol and advancements in clinical trials involving aldoxorubicin.

CytRx Corporation (OTCQB: CYTR) highlights Orphazyme's new investor presentation regarding the upcoming potential U.S. and European approval of arimoclomol for Niemann-Pick disease Type C (NPC). Key points include arimoclomol being first to market for NPC in the U.S., an expected decision on European approval by Q4 2021, and sales projections of up to $20 million this year. CytRx has a financial agreement with Orphazyme for milestone payments and royalties on arimoclomol sales.

CytRx Corporation (OTCQB: CYTR) announces that Orphazyme A/S appointed Christophe Bourdon as CEO, effective April 1, 2021. Orphazyme is awaiting FDA approval for arimoclomol, intended for Niemann-Pick disease Type C (NPC). CytRx has a revenue-sharing agreement with Orphazyme, which includes milestone payments and royalties on arimoclomol sales. Bourdon brings extensive experience from Amgen and Alexion, enhancing Orphazyme's prospects. CytRx’s chairman views this leadership change as a positive step towards successful commercialization of arimoclomol, which targets four orphan diseases.

CytRx Corporation (OTCQB: CYTR) announced that its CEO, Steven A. Kriegsman, will participate in two upcoming conferences. First, he will deliver a virtual presentation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, available for on-demand viewing. Following this, he will present at the Virtual 33rd Annual ROTH Conference from March 15-17, 2021, with access starting on March 5, 2021 on CytRx's website. CytRx focuses on developing therapeutics for cancer and neurodegenerative diseases.

CytRx Corporation (OTCQB: CYTR) has joined the LD Micro Index, which tracks microcap stocks in North America. The Index includes 1,189 companies with market capitalizations between $50 million and $300 million. CytRx's Chairman, Steven A. Kriegsman, expressed optimism about the company's future, especially regarding the drug aldoxorubicin and its potential in cancer treatment. This advancement follows positive interim results in related clinical trials.

CytRx Corporation (OTCQB:CYTR) reports encouraging interim results from Phase 2 clinical trials conducted by NantKwest and ImmunityBio involving its licensed drug aldoxorubicin for advanced pancreatic cancer. The trials, known as QUILT 88, showed median survival rates more than doubling the historic rate for patients with no approved treatment options. Notably, 83% of patients in Cohort C remain alive. The trials aim to evaluate the efficacy of a novel combination immunotherapy, promising a potential breakthrough in treatment protocols for an aggressive cancer type.